ReviewMolecular diagnosis & therapy2014
Defining phenotypes in COPD: an aid to personalized healthcare.
Review in Molecular diagnosis & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2015Pooled it
- Single-Breath Simultaneous Measurement of DLInternational journal of chronic obstructive pulmonary disease · 2024Observational
- Emerging Anti-Inflammatory COPD Treatments: Potential Cardiovascular Impacts.International journal of chronic obstructive pulmonary disease · 2024Review
- Novel Anti-Inflammatory Approaches to COPD.International journal of chronic obstructive pulmonary disease · 2023Review
- Prevalence and clinical features of most frequent phenotypes in the Italian COPD population: the CLIMA Study.Multidisciplinary respiratory medicine · 2021Article
- Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers.Molecular diagnosis & therapy · 2019Review
- Annotating and detecting phenotypic information for chronic obstructive pulmonary disease.JAMIA open · 2019Article
- Noninvasive Ventilation Weaning in Acute Hypercapnic Respiratory Failure due to COPD Exacerbation: A Real-Life Observational Study.Canadian respiratory journal · 2019Observational
- Chronic obstructive pulmonary disease in non-smokers - Is it a different phenotype?The Indian journal of medical research · 2018Article
- Use of clinical characteristics to predict spirometric classification of obstructive lung disease.International journal of chronic obstructive pulmonary disease · 2018Article
- Biomarkers of collagen turnover are related to annual change in FEVBMC pulmonary medicine · 2017Observational
- The Challenges of Precision Medicine in COPD.Molecular diagnosis & therapy · 2017Article
- Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD.Respiratory research · 2017Article
- Dual bronchodilation and exacerbations of COPD.Journal of thoracic disease · 2016Article
- Asthma and chronic obstructive pulmonary disease overlap syndrome (ACOS): structured literature review and physician insights.Expert review of respiratory medicine · 2016Review
- Airflow obstruction: is it asthma or is it COPD?International journal of chronic obstructive pulmonary disease · 2016Review
- The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils.BioMed research international · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of chronic obstructive pulmonary disease (COPD) is based on a post-bronchodilator fixed forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) <70 % ratio and the presence of symptoms such as shortness of breath and productive cough. Despite the simplicity in making a diagnosis of COPD, this morbid condition is very heterogeneous, and at least three different phenotypes can be recognized: the exacerbator, the emphysema-hyperinflation and the overlap COPD-asthma. These subgroups show different clinical and radiological features. It has been speculated that there is an enormous variability in the response to drugs among the COPD phenotypes, and it is expected that subjects with the same phenotype will have a similar response to each specific treatment. We believe that phenotyping COPD patients would be very useful to predict the response to a treatment and the progression of the disease. This personalized approach allows identification of the right treatment for each COPD patient, and at the same time, leads to improvement in the effectiveness of therapies, avoidance of treatments not indicated, and reduction in the onset of adverse effects. The objective of the present review is to report the current knowledge about different COPD phenotypes, focusing on specific treatments for each subgroup. However, at present, COPD phenotypes have not been studied by randomized clinical trials and therefore we hope that well designed studies will focus on this topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.